MDS, AML a Risk With PARP Inhibitors in BRCA Mutation Carriers

Share this content:
Reviewing a prescription with an older patient.
Reviewing a prescription with an older patient.

What is the concern behind PARP inhibitors and leukemia? — Name withheld on request

Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients receiving poly(ADP-ribose) polymerase (PARP) inhibitors such as olaparib (Lynparza), rucaparib (Rubraca), and niraparib (Zejula). Warnings about MDS or AML are listed in the prescribing information for the above the PARP inhibitors currently used in the United States.

MDS or AML has been reported in 0.5% to 2% of patients taking the various approved PARP inhibitors. Reports indicate that the patients had received prior treatment with platinum-based chemotherapy or other DNA-damaging agents, and most of the cases of MDS and AML were reported in patients with BRCA mutations.

BRCA gene is involved with repair of DNA damage, and defects in DNA repair may increase the risk of developing MDS or AML. Because of this, MDS or AML are more of a concern in patients with BRCA mutations.

Regular monthly monitoring of complete blood counts (CBC) are recommended for patients taking PARP inhibitors. Patients with prolonged hematologic abnormalities should undergo further evaluation. If the patient develops MDS or AML, the PARP inhibitor should be discontinued.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs